DALBAVANCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dalbavancin, and what generic alternatives are available?
Dalbavancin is a drug marketed by Be Pharms, Fresenius Kabi Usa, Kindos, Long Grove Pharms, and Teva Pharms Inc. and is included in five NDAs.
The generic ingredient in DALBAVANCIN is dalbavancin hydrochloride. Seven suppliers are listed for this compound. Additional details are available on the dalbavancin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dalbavancin
A generic version of DALBAVANCIN was approved as dalbavancin hydrochloride by TEVA PHARMS INC on October 23rd, 2025.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DALBAVANCIN?
- What are the global sales for DALBAVANCIN?
- What is Average Wholesale Price for DALBAVANCIN?
Summary for DALBAVANCIN
| US Patents: | 0 |
| Applicants: | 5 |
| NDAs: | 5 |
| DailyMed Link: | DALBAVANCIN at DailyMed |
US Patents and Regulatory Information for DALBAVANCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Be Pharms | DALBAVANCIN HYDROCHLORIDE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 219604-001 | Jun 4, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Long Grove Pharms | DALBAVANCIN HYDROCHLORIDE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 218602-001 | Feb 26, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Fresenius Kabi Usa | DALBAVANCIN HYDROCHLORIDE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 217591-001 | Nov 10, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Kindos | DALBAVANCIN HYDROCHLORIDE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 218929-001 | Nov 26, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
